EDITORIALS
The place of varenicline in smoking cessation treatment
Correspondence to:
Dr Paul Aveyard, Division of Primary Care and Public Health, University of Birmingham, Birmingham B15 2TT, UK; p.n.aveyard@bham.ac.uk
| The first 150 words of the full text of this article appear below. |
In this issue of Thorax Aubin and colleagues1 report a further trial from the Varenicline Phase III Programme (see page 717). The trials supporting registration contrasted bupropion with varenicline in a double placebo design.2 3 This study examines the efficacy of varenicline against nicotine replacement therapy (NRT). In many countries, including the UK, bupropion is rarely used and NRT is the predominant treatment offered in general practices and in specialist smoking cessation clinics. It is not practical to obtain placebo NRT, so this trial was of an open-label design. This publication follows a study by Stapleton et al4 with historical controls which showed that varenicline is superior to NRT in achieving abstinence and in reducing withdrawal phenomena such as urges to smoke and withdrawal symptoms.
Varenicline is licensed for smoking cessation around the world, but in the UK the National Institute for Health and Clinical Excellence (NICE) makes decisions
Relevant Articles
- Airwaves
- Wisia Wedzicha
Thorax 2008 63: 663.[Extract] [Full Text] [PDF]
- Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial
- H-J Aubin, A Bobak, J R Britton, C Oncken, C B Billing, Jr, J Gong, K E Williams, and K R Reeves
Thorax 2008 63: 717-724.[Abstract] [Full Text] [PDF]
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
